You are here

Serum Inflammasome proteins: Novel biomarker panel for radiation biodosimetry

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41ES031778-01
Agency Tracking Number: R41ES031778
Amount: $301,260.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIEHS
Solicitation Number: PA18-575
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-09-10
Award End Date (Contract End Date): 2020-08-31
Small Business Information
900 MERRYBELL LN, Kennett Square, PA, 19348-2733
DUNS: 080473448
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 (610) 299-7482
Business Contact
Phone: (610) 299-7482
Research Institution
PHILADELPHIA, PA, 19104-6205
 Nonprofit college or university
JT MeSh diagnostics is developing novel biodosimeter devices which will allow for rapidsimpleon site mass screening in the event of a nuclear disaster or an act of terrorismdirty bombBiodosimeters are critical in the event of a large scale radiological emergencyin the form of a nuclear disasterterrorist attack or radiation exposure of military personnelwhere a large population ofexposedindividuals need immediate appropriate medical care or assigned to triageThe current biodosimetry markers that are in use monitor clusters of potential biodosimetry genes or proteins that are radio sensitivehowever such detection procedures involve invasive proceduresspecific cells that need to be isolated from peripheral bloodlong processing timesspecialized facilities and technical expertise for data evaluationThus these assays although accurateare unsuitable for mass casualty screening at the site of the radiological eventWe propose to use a panel of inflammasome proteins that have been reported to be radiosensitive and are also part of the cellulardangersensing machineryThese proteins were chosen based on their radiosensitivity and their ability to be secreted from the tissue and vascular network into the circulation and we propose the use of these blood inflammasome proteins as potential radiation biodosimetry panelJT MeSH Diagnostics selectedinflammasome proteins which will be evaluated in this Phase I application as part of a potential biodosimeter panelWe propose to use an in vitro vascular network model to evaluate the panel ofinflammasome proteins as a radiation biodosimeter and to validate this panel as a radiation biodosimeter in an in vivo model of thoracic radiationThese studies will form the basis of a portable miniature platform that will allow rapid detection of inflammasome protein using a blood drop sampleThe JT MeSH Diagnostics device for mass casualty screening will rapidly determine if individuals were exposed to radiationi eirradiated non irradiatedand the level of exposure in a single easy and rapid test in a simple to use biodosimeter JT MeSH Diagnostics LLC is developing a panel ofinflammasome proteins found in the blood as a panel biodosimeter which will allow for rapidsimpleon site mass screening in the event of a nuclear disaster or an act of terrorismdirty bombThe proposed work will validate the panel and these studies will form the basis of developing amultiple samplingfirst responder screening toolto stratify individuals post radiological emergencies

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government